September 14, 2017 09:38 AM EDT
R&D

New PhI­II da­ta in hand, Pfiz­er, Astel­las hus­tle ahead in bid to ex­pand US mar­ket for Xtan­di

John Carroll

Editor & Founder

Pfiz­er $PFE just got some bad­ly need­ed good news for its new­ly ac­quired can­cer drug Xtan­di.

Af­ter watch­ing sales sink right af­ter it ac­quired the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

A service from the Financial Times